Final Examination
NR 568 / NR568
Advanced Pharmacology for the
Adult-Gerontology Primary Care
Nurse Practitioner (AGPCNP)
Questions with Answers
Latest Update
Aligned with Chamberlain University NR568 Curriculum Standards
and AGPCNP Certification Competencies
120 Questions | 9 Sections | Multiple Choice
Passing Score: 70%
,NR 568 Advanced Pharmacology Final Examination | Questions with Answers Latest Update 2026/2027
Section 1: Principles of Pharmacology and Pharmacokinetics
Questions 1-15 | Pharmacokinetics, Pharmacodynamics, Drug Interactions, Pharmacogenomics, ADRs, Medication Safety
Q1. A 68-year-old patient with atrial fibrillation is prescribed warfarin for stroke prevention. The nurse
practitioner notes that the patient has been taking St. John's Wort for depression. Which pharmacokinetic
interaction is most likely to occur, and what is the clinical significance?
A. Decreased warfarin absorption due to altered gastric pH, reducing anticoagulant effect
B. Enhanced protein binding of warfarin, increasing free drug levels and bleeding risk
C. Induction of CYP2C9 metabolism of warfarin, decreasing INR and increasing thromboembolic risk [CORRECT]
D. Inhibition of CYP3A4 metabolism of warfarin, increasing INR and bleeding risk
Correct Answer: C
Rationale: St. John's Wort is a potent CYP450 inducer, particularly affecting CYP2C9, which is the primary enzyme responsible
for metabolizing the S-enantiomer of warfarin (the more active form). Induction accelerates warfarin metabolism, leading to
decreased INR and increased risk of thromboembolic events such as stroke. Option A is incorrect because St. John's Wort does not
significantly affect gastric pH or absorption. Option B is incorrect because warfarin is already highly protein-bound (99%), and St.
John's Wort does not further enhance this binding. Option D is incorrect because St. John's Wort induces, not inhibits, CYP
enzymes. This interaction is well-documented and requires careful monitoring when patients are prescribed warfarin alongside CYP
inducers such as St. John's Wort, rifampin, phenytoin, and carbamazepine.
Q2. A nurse practitioner is educating a patient newly prescribed lisinopril. Which statement best explains the
concept of bioavailability as it relates to this medication?
A. Bioavailability refers to the percentage of the administered dose that reaches the systemic circulation unchanged
[CORRECT]
B. Bioavailability is the rate at which lisinopril is excreted by the kidneys
C. Bioavailability describes the degree of protein binding of lisinopril in plasma
D. Bioavailability is the volume of distribution of lisinopril in body tissues
Correct Answer: A
Rationale: Bioavailability (F) is the fraction of an administered dose of unchanged drug that reaches the systemic circulation,
making it available at the site of action. For orally administered drugs, bioavailability is influenced by absorption and first-pass
hepatic metabolism. Lisinopril is unique among ACE inhibitors because it has high oral bioavailability (approximately 25%, but
notably it does not undergo first-pass metabolism), unlike enalapril which is a prodrug requiring hepatic conversion. Option B
describes clearance or excretion, not bioavailability. Option C refers to the pharmacokinetic concept of protein binding, which
determines the fraction of free (active) drug. Option D describes volume of distribution, a measure of how widely a drug distributes
in the body.
Q3. A 55-year-old woman with heart failure and reduced ejection fraction is prescribed digoxin. Her current serum
creatinine is 1.8 mg/dL. Which pharmacokinetic alteration in renal impairment most significantly affects digoxin
dosing in this patient?
A. Decreased protein binding leads to higher free drug levels and increased therapeutic effect
B. Reduced renal clearance of digoxin leads to drug accumulation and increased risk of toxicity [CORRECT]
C. Increased hepatic metabolism of digoxin requires higher doses for therapeutic effect
D. Enhanced first-pass metabolism reduces the effective bioavailable dose
Correct Answer: B
Rationale: Digoxin is primarily eliminated by renal excretion (approximately 60-80% unchanged). In patients with renal
impairment (elevated creatinine), the clearance of digoxin is significantly reduced, leading to drug accumulation and increased risk
Chamberlain University Page 2
,NR 568 Advanced Pharmacology Final Examination | Questions with Answers Latest Update 2026/2027
of digoxin toxicity (nausea, vomiting, visual disturbances such as yellow-tinged vision, cardiac arrhythmias). The narrow
therapeutic index (0.5-2.0 ng/mL) makes digoxin particularly dangerous in renal impairment, and dose reduction is mandatory. The
Beers Criteria specifically warns that digoxin doses greater than 0.125 mg/day should be avoided in older adults due to decreased
renal clearance. Option A is incorrect because digoxin protein binding is relatively low and not significantly altered in renal
impairment. Option C is incorrect because digoxin undergoes minimal hepatic metabolism. Option D is incorrect because digoxin is
not subject to significant first-pass metabolism.
Q4. A 72-year-old patient with a serum albumin of 2.8 g/dL (low) is prescribed warfarin. How does decreased
albumin most significantly affect the pharmacokinetics of this highly protein-bound drug?
A. Decreased albumin leads to reduced hepatic metabolism of warfarin
B. Lower albumin increases the free (unbound) fraction of warfarin, potentially increasing its anticoagulant effect
[CORRECT]
C. Reduced albumin binding increases the renal clearance of warfarin
D. Lower albumin decreases warfarin absorption from the gastrointestinal tract
Correct Answer: B
Rationale: Warfarin is approximately 99% protein-bound, primarily to albumin. When serum albumin is low (hypoalbuminemia),
fewer binding sites are available, leading to an increase in the free (unbound) fraction of warfarin. Since only free drug is
pharmacologically active, this can lead to an enhanced anticoagulant effect and increased bleeding risk, even though the total serum
warfarin concentration may appear therapeutic. This is especially important in geriatric patients, malnourished patients, and those
with chronic liver disease. Option A is incorrect because protein binding does not directly affect hepatic metabolism. Option C is
incorrect because only free drug is available for renal clearance; increased free fraction could theoretically increase clearance, but
the clinical effect of increased free active drug dominates. Option D is incorrect because protein binding occurs after absorption and
does not affect the absorption process.
Q5. A patient is prescribed a medication with a half-life of 12 hours. Approximately how long will it take for this
drug to reach steady-state concentrations with repeated dosing?
A. 12 hours
B. 24 hours
C. 60 hours (approximately 5 half-lives) [CORRECT]
D. 120 hours (approximately 10 half-lives)
Correct Answer: C
Rationale: Steady-state concentration is achieved when the rate of drug administration equals the rate of drug elimination. For a
drug following first-order kinetics, steady state is reached after approximately 4-5 half-lives. With a half-life of 12 hours, steady
state would be achieved in approximately 60 hours (5 x 12 = 60 hours). At 4 half-lives (48 hours), approximately 94% of steady
state is reached, and at 5 half-lives (60 hours), approximately 97% is reached. This principle is clinically important because drug
effects, therapeutic monitoring, and assessment of efficacy should generally not be performed until steady state is reached. Option A
(one half-life) reaches only 50% of steady state. Option B (two half-lives) reaches 75%. Option D (10 half-lives) far exceeds the
necessary time.
Q6. A 30-year-old female patient of Ashkenazi Jewish descent is being considered for initiation of abacavir (an
antiretroviral medication). Which pharmacogenomic test is mandatory before prescribing this medication?
A. CYP2D6 genotype testing to assess metabolizer status
B. HLA-B*5701 allele testing to assess risk of hypersensitivity reaction [CORRECT]
C. VKORC1 polymorphism testing to assess warfarin sensitivity
D. CYP2C19 genotype testing to assess clopidogrel metabolism
Correct Answer: B
Rationale: The HLA-B*5701 allele is strongly associated with abacavir hypersensitivity syndrome, a potentially life-threatening
systemic reaction characterized by fever, rash, gastrointestinal symptoms, and respiratory distress. FDA guidelines mandate
Chamberlain University Page 3
, NR 568 Advanced Pharmacology Final Examination | Questions with Answers Latest Update 2026/2027
HLA-B*5701 testing before initiating abacavir, and the drug is contraindicated in patients who test positive. The prevalence of
HLA-B*5701 is highest in individuals of Ashkenazi Jewish descent (approximately 8%), making pre-prescribing testing especially
important in this population. Option A (CYP2D6) is relevant for medications like codeine and tricyclic antidepressants, not
abacavir. Option C (VKORC1) is relevant for warfarin dosing. Option D (CYP2C19) is relevant for clopidogrel activation and
proton pump inhibitor metabolism.
Q7. A 25-year-old patient receives penicillin G intravenously and within minutes develops urticaria, angioedema,
wheezing, and hypotension. Which type of hypersensitivity reaction is this, and what is the mechanism?
A. Type II (Cytotoxic) reaction involving IgG/IgM-mediated complement activation
B. Type III (Immune complex) reaction involving antigen-antibody complex deposition
C. Type I (Anaphylactic) reaction involving IgE-mediated mast cell and basophil degranulation [CORRECT]
D. Type IV (Delayed hypersensitivity) reaction involving T-cell mediated inflammation
Correct Answer: C
Rationale: This presentation is a classic Type I (IgE-mediated) anaphylactic reaction. Penicillin is one of the most common causes
of drug-induced anaphylaxis. The mechanism involves prior sensitization producing IgE antibodies that bind to mast cells and
basophils. Upon re-exposure, the penicillin antigen cross-links IgE on these cells, triggering degranulation and release of histamine,
tryptase, leukotrienes, and other mediators. Clinical manifestations range from urticaria and angioedema to life-threatening
bronchospasm and cardiovascular collapse. Immediate treatment includes epinephrine (first-line), antihistamines, corticosteroids,
and supportive care. Option A (Type II) involves IgG/IgM targeting cell surfaces, as seen in drug-induced hemolytic anemia. Option
B (Type III) involves immune complex deposition, as seen in serum sickness. Option D (Type IV) is T-cell mediated and delayed
(24-72 hours), as seen in contact dermatitis.
Q8. A nurse practitioner is comparing two drugs for the same condition. Drug A produces a maximal therapeutic
effect at 10 mg, while Drug B produces the same maximal effect but requires 50 mg to achieve it. Which
pharmacodynamic concept best describes this difference?
A. Drug A has greater efficacy than Drug B
B. Drug A has greater potency than Drug B [CORRECT]
C. Drug A has a wider therapeutic index than Drug B
D. Drug A has a longer half-life than Drug B
Correct Answer: B
Rationale: Potency refers to the amount (concentration or dose) of drug needed to produce a given effect, typically measured as the
ED50 (effective dose for 50% of maximal response). Drug A requires 10 mg to achieve the same maximal effect that Drug B
achieves at 50 mg, making Drug A five times more potent. Both drugs have the same maximal effect (efficacy), so option A is
incorrect. The therapeutic index (option C) relates the dose producing toxicity (TD50 or LD50) to the dose producing the
therapeutic effect (ED50), which is not described in this scenario. Half-life (option D) is a pharmacokinetic parameter related to
elimination rate, not the dose-response relationship.
Q9. A patient taking fluoxetine (a CYP2D6 inhibitor) is prescribed tramadol for chronic pain. What is the most
significant pharmacokinetic interaction, and what clinical effect is expected?
A. Fluoxetine induces CYP2D6, leading to faster tramadol metabolism and reduced analgesic effect
B. Fluoxetine inhibits CYP2D6, reducing conversion of tramadol to its active metabolite (O-desmethyltramadol) and
decreasing analgesic efficacy [CORRECT]
C. Fluoxetine inhibits CYP3A4, leading to tramadol accumulation and increased risk of seizures
D. Fluoxetine increases protein binding of tramadol, reducing its free concentration and effect
Correct Answer: B
Rationale: Tramadol is a prodrug that requires CYP2D6-mediated O-demethylation to produce its active metabolite,
O-desmethyltramadol (M1), which is responsible for the majority of tramadol's opioid analgesic effect. Fluoxetine is a potent
CYP2D6 inhibitor, which reduces the conversion of tramadol to M1, thereby decreasing analgesic efficacy. Additionally, the parent
Chamberlain University Page 4
NR 568 / NR568
Advanced Pharmacology for the
Adult-Gerontology Primary Care
Nurse Practitioner (AGPCNP)
Questions with Answers
Latest Update
Aligned with Chamberlain University NR568 Curriculum Standards
and AGPCNP Certification Competencies
120 Questions | 9 Sections | Multiple Choice
Passing Score: 70%
,NR 568 Advanced Pharmacology Final Examination | Questions with Answers Latest Update 2026/2027
Section 1: Principles of Pharmacology and Pharmacokinetics
Questions 1-15 | Pharmacokinetics, Pharmacodynamics, Drug Interactions, Pharmacogenomics, ADRs, Medication Safety
Q1. A 68-year-old patient with atrial fibrillation is prescribed warfarin for stroke prevention. The nurse
practitioner notes that the patient has been taking St. John's Wort for depression. Which pharmacokinetic
interaction is most likely to occur, and what is the clinical significance?
A. Decreased warfarin absorption due to altered gastric pH, reducing anticoagulant effect
B. Enhanced protein binding of warfarin, increasing free drug levels and bleeding risk
C. Induction of CYP2C9 metabolism of warfarin, decreasing INR and increasing thromboembolic risk [CORRECT]
D. Inhibition of CYP3A4 metabolism of warfarin, increasing INR and bleeding risk
Correct Answer: C
Rationale: St. John's Wort is a potent CYP450 inducer, particularly affecting CYP2C9, which is the primary enzyme responsible
for metabolizing the S-enantiomer of warfarin (the more active form). Induction accelerates warfarin metabolism, leading to
decreased INR and increased risk of thromboembolic events such as stroke. Option A is incorrect because St. John's Wort does not
significantly affect gastric pH or absorption. Option B is incorrect because warfarin is already highly protein-bound (99%), and St.
John's Wort does not further enhance this binding. Option D is incorrect because St. John's Wort induces, not inhibits, CYP
enzymes. This interaction is well-documented and requires careful monitoring when patients are prescribed warfarin alongside CYP
inducers such as St. John's Wort, rifampin, phenytoin, and carbamazepine.
Q2. A nurse practitioner is educating a patient newly prescribed lisinopril. Which statement best explains the
concept of bioavailability as it relates to this medication?
A. Bioavailability refers to the percentage of the administered dose that reaches the systemic circulation unchanged
[CORRECT]
B. Bioavailability is the rate at which lisinopril is excreted by the kidneys
C. Bioavailability describes the degree of protein binding of lisinopril in plasma
D. Bioavailability is the volume of distribution of lisinopril in body tissues
Correct Answer: A
Rationale: Bioavailability (F) is the fraction of an administered dose of unchanged drug that reaches the systemic circulation,
making it available at the site of action. For orally administered drugs, bioavailability is influenced by absorption and first-pass
hepatic metabolism. Lisinopril is unique among ACE inhibitors because it has high oral bioavailability (approximately 25%, but
notably it does not undergo first-pass metabolism), unlike enalapril which is a prodrug requiring hepatic conversion. Option B
describes clearance or excretion, not bioavailability. Option C refers to the pharmacokinetic concept of protein binding, which
determines the fraction of free (active) drug. Option D describes volume of distribution, a measure of how widely a drug distributes
in the body.
Q3. A 55-year-old woman with heart failure and reduced ejection fraction is prescribed digoxin. Her current serum
creatinine is 1.8 mg/dL. Which pharmacokinetic alteration in renal impairment most significantly affects digoxin
dosing in this patient?
A. Decreased protein binding leads to higher free drug levels and increased therapeutic effect
B. Reduced renal clearance of digoxin leads to drug accumulation and increased risk of toxicity [CORRECT]
C. Increased hepatic metabolism of digoxin requires higher doses for therapeutic effect
D. Enhanced first-pass metabolism reduces the effective bioavailable dose
Correct Answer: B
Rationale: Digoxin is primarily eliminated by renal excretion (approximately 60-80% unchanged). In patients with renal
impairment (elevated creatinine), the clearance of digoxin is significantly reduced, leading to drug accumulation and increased risk
Chamberlain University Page 2
,NR 568 Advanced Pharmacology Final Examination | Questions with Answers Latest Update 2026/2027
of digoxin toxicity (nausea, vomiting, visual disturbances such as yellow-tinged vision, cardiac arrhythmias). The narrow
therapeutic index (0.5-2.0 ng/mL) makes digoxin particularly dangerous in renal impairment, and dose reduction is mandatory. The
Beers Criteria specifically warns that digoxin doses greater than 0.125 mg/day should be avoided in older adults due to decreased
renal clearance. Option A is incorrect because digoxin protein binding is relatively low and not significantly altered in renal
impairment. Option C is incorrect because digoxin undergoes minimal hepatic metabolism. Option D is incorrect because digoxin is
not subject to significant first-pass metabolism.
Q4. A 72-year-old patient with a serum albumin of 2.8 g/dL (low) is prescribed warfarin. How does decreased
albumin most significantly affect the pharmacokinetics of this highly protein-bound drug?
A. Decreased albumin leads to reduced hepatic metabolism of warfarin
B. Lower albumin increases the free (unbound) fraction of warfarin, potentially increasing its anticoagulant effect
[CORRECT]
C. Reduced albumin binding increases the renal clearance of warfarin
D. Lower albumin decreases warfarin absorption from the gastrointestinal tract
Correct Answer: B
Rationale: Warfarin is approximately 99% protein-bound, primarily to albumin. When serum albumin is low (hypoalbuminemia),
fewer binding sites are available, leading to an increase in the free (unbound) fraction of warfarin. Since only free drug is
pharmacologically active, this can lead to an enhanced anticoagulant effect and increased bleeding risk, even though the total serum
warfarin concentration may appear therapeutic. This is especially important in geriatric patients, malnourished patients, and those
with chronic liver disease. Option A is incorrect because protein binding does not directly affect hepatic metabolism. Option C is
incorrect because only free drug is available for renal clearance; increased free fraction could theoretically increase clearance, but
the clinical effect of increased free active drug dominates. Option D is incorrect because protein binding occurs after absorption and
does not affect the absorption process.
Q5. A patient is prescribed a medication with a half-life of 12 hours. Approximately how long will it take for this
drug to reach steady-state concentrations with repeated dosing?
A. 12 hours
B. 24 hours
C. 60 hours (approximately 5 half-lives) [CORRECT]
D. 120 hours (approximately 10 half-lives)
Correct Answer: C
Rationale: Steady-state concentration is achieved when the rate of drug administration equals the rate of drug elimination. For a
drug following first-order kinetics, steady state is reached after approximately 4-5 half-lives. With a half-life of 12 hours, steady
state would be achieved in approximately 60 hours (5 x 12 = 60 hours). At 4 half-lives (48 hours), approximately 94% of steady
state is reached, and at 5 half-lives (60 hours), approximately 97% is reached. This principle is clinically important because drug
effects, therapeutic monitoring, and assessment of efficacy should generally not be performed until steady state is reached. Option A
(one half-life) reaches only 50% of steady state. Option B (two half-lives) reaches 75%. Option D (10 half-lives) far exceeds the
necessary time.
Q6. A 30-year-old female patient of Ashkenazi Jewish descent is being considered for initiation of abacavir (an
antiretroviral medication). Which pharmacogenomic test is mandatory before prescribing this medication?
A. CYP2D6 genotype testing to assess metabolizer status
B. HLA-B*5701 allele testing to assess risk of hypersensitivity reaction [CORRECT]
C. VKORC1 polymorphism testing to assess warfarin sensitivity
D. CYP2C19 genotype testing to assess clopidogrel metabolism
Correct Answer: B
Rationale: The HLA-B*5701 allele is strongly associated with abacavir hypersensitivity syndrome, a potentially life-threatening
systemic reaction characterized by fever, rash, gastrointestinal symptoms, and respiratory distress. FDA guidelines mandate
Chamberlain University Page 3
, NR 568 Advanced Pharmacology Final Examination | Questions with Answers Latest Update 2026/2027
HLA-B*5701 testing before initiating abacavir, and the drug is contraindicated in patients who test positive. The prevalence of
HLA-B*5701 is highest in individuals of Ashkenazi Jewish descent (approximately 8%), making pre-prescribing testing especially
important in this population. Option A (CYP2D6) is relevant for medications like codeine and tricyclic antidepressants, not
abacavir. Option C (VKORC1) is relevant for warfarin dosing. Option D (CYP2C19) is relevant for clopidogrel activation and
proton pump inhibitor metabolism.
Q7. A 25-year-old patient receives penicillin G intravenously and within minutes develops urticaria, angioedema,
wheezing, and hypotension. Which type of hypersensitivity reaction is this, and what is the mechanism?
A. Type II (Cytotoxic) reaction involving IgG/IgM-mediated complement activation
B. Type III (Immune complex) reaction involving antigen-antibody complex deposition
C. Type I (Anaphylactic) reaction involving IgE-mediated mast cell and basophil degranulation [CORRECT]
D. Type IV (Delayed hypersensitivity) reaction involving T-cell mediated inflammation
Correct Answer: C
Rationale: This presentation is a classic Type I (IgE-mediated) anaphylactic reaction. Penicillin is one of the most common causes
of drug-induced anaphylaxis. The mechanism involves prior sensitization producing IgE antibodies that bind to mast cells and
basophils. Upon re-exposure, the penicillin antigen cross-links IgE on these cells, triggering degranulation and release of histamine,
tryptase, leukotrienes, and other mediators. Clinical manifestations range from urticaria and angioedema to life-threatening
bronchospasm and cardiovascular collapse. Immediate treatment includes epinephrine (first-line), antihistamines, corticosteroids,
and supportive care. Option A (Type II) involves IgG/IgM targeting cell surfaces, as seen in drug-induced hemolytic anemia. Option
B (Type III) involves immune complex deposition, as seen in serum sickness. Option D (Type IV) is T-cell mediated and delayed
(24-72 hours), as seen in contact dermatitis.
Q8. A nurse practitioner is comparing two drugs for the same condition. Drug A produces a maximal therapeutic
effect at 10 mg, while Drug B produces the same maximal effect but requires 50 mg to achieve it. Which
pharmacodynamic concept best describes this difference?
A. Drug A has greater efficacy than Drug B
B. Drug A has greater potency than Drug B [CORRECT]
C. Drug A has a wider therapeutic index than Drug B
D. Drug A has a longer half-life than Drug B
Correct Answer: B
Rationale: Potency refers to the amount (concentration or dose) of drug needed to produce a given effect, typically measured as the
ED50 (effective dose for 50% of maximal response). Drug A requires 10 mg to achieve the same maximal effect that Drug B
achieves at 50 mg, making Drug A five times more potent. Both drugs have the same maximal effect (efficacy), so option A is
incorrect. The therapeutic index (option C) relates the dose producing toxicity (TD50 or LD50) to the dose producing the
therapeutic effect (ED50), which is not described in this scenario. Half-life (option D) is a pharmacokinetic parameter related to
elimination rate, not the dose-response relationship.
Q9. A patient taking fluoxetine (a CYP2D6 inhibitor) is prescribed tramadol for chronic pain. What is the most
significant pharmacokinetic interaction, and what clinical effect is expected?
A. Fluoxetine induces CYP2D6, leading to faster tramadol metabolism and reduced analgesic effect
B. Fluoxetine inhibits CYP2D6, reducing conversion of tramadol to its active metabolite (O-desmethyltramadol) and
decreasing analgesic efficacy [CORRECT]
C. Fluoxetine inhibits CYP3A4, leading to tramadol accumulation and increased risk of seizures
D. Fluoxetine increases protein binding of tramadol, reducing its free concentration and effect
Correct Answer: B
Rationale: Tramadol is a prodrug that requires CYP2D6-mediated O-demethylation to produce its active metabolite,
O-desmethyltramadol (M1), which is responsible for the majority of tramadol's opioid analgesic effect. Fluoxetine is a potent
CYP2D6 inhibitor, which reduces the conversion of tramadol to M1, thereby decreasing analgesic efficacy. Additionally, the parent
Chamberlain University Page 4
